{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:35:55Z","timestamp":1787726155856,"version":"build-2784847793"},"reference-count":28,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme United Kingdom","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004628","name":"AstraZeneca UK Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004628","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ijgc.2025.101645","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T00:04:42Z","timestamp":1737158682000},"page":"101645","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Prevalence of homologous recombination deficiency among women with newly diagnosed ovarian, primary peritoneal, and\/or fallopian tube cancer: the international HALO study"],"prefix":"10.1016","volume":"35","author":[{"given":"Svetlana","family":"Khokhlova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manwar Abdulelah","family":"Alnaqqash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waleed","family":"Bahaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salha","family":"Bujassoum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jooyeon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Mokhtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Tyulyandina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4834-7305","authenticated-orcid":false,"given":"Carmen Luz","family":"Vargas Malaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Hsuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ijgc.2025.101645_bib1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/oncolo\/oyab053","article-title":"Homologous recombination deficiency: concepts, definitions, and assays","volume":"27","author":"Stewart","year":"2022","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101645_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.16.00031","article-title":"Homologous recombination deficiency in breast cancer: a clinical review","volume":"1","author":"den Brok","year":"2017","journal-title":"JCO Precis Oncol"},{"issue":"7353","key":"10.1016\/j.ijgc.2025.101645_bib3","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","year":"2011","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.ijgc.2025.101645_bib4","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1158\/2159-8290.CD-15-0714","article-title":"Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer","volume":"5","author":"Konstantinopoulos","year":"2015","journal-title":"Cancer Discov."},{"issue":"suppl 1","key":"10.1016\/j.ijgc.2025.101645_bib5","article-title":"Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management","volume":"73","author":"da Cunha Colombo Bonadio","year":"2018","journal-title":"Clinics (Sao Paulo)"},{"issue":"25","key":"10.1016\/j.ijgc.2025.101645_bib6","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N Engl J Med."},{"issue":"8","key":"10.1016\/j.ijgc.2025.101645_bib7","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/jjco\/hyz090","article-title":"PARP inhibitors for BRCA wild type ovarian cancer; gene alterations, homologous recombination deficiency and combination therapy","volume":"49","author":"Matsumoto","year":"2019","journal-title":"Jpn J Clin Oncol."},{"key":"10.1016\/j.ijgc.2025.101645_bib8","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40661-017-0039-8","article-title":"Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature","volume":"4","author":"Frey","year":"2017","journal-title":"Gynecol Oncol Res Pract"},{"issue":"25","key":"10.1016\/j.ijgc.2025.101645_bib9","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ijgc.2025.101645_bib10","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","article-title":"Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial","volume":"34","author":"Ray-Coquard","year":"2023","journal-title":"Ann Oncol"},{"issue":"34","key":"10.1016\/j.ijgc.2025.101645_bib11","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1200\/JCO.22.01003","article-title":"A randomized, Phase III trial to evaluate Rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO\/GOG-3020\/ENGOT-ov45)","volume":"40","author":"Monk","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijgc.2025.101645_bib12","unstructured":"LYNPARZA (olaparib). Food and Drug Administration. Accessed January 11, 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/208558s025lbl.pdf."},{"key":"10.1016\/j.ijgc.2025.101645_bib13","unstructured":"ZEJULA (niraparib). Food and Drug Administration. Accessed September 18, 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/214876s000lbl.pdf."},{"key":"10.1016\/j.ijgc.2025.101645_bib14","unstructured":"RUBRACA (rucaparib). Food and Drug Administration. Accessed September 12, 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/209115s011lbl.pdf."},{"issue":"10","key":"10.1016\/j.ijgc.2025.101645_bib15","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.annonc.2021.07.004","article-title":"Updated treatment recommendations for newly diagnosed epithelial ovarian carcinoma from the ESMO Clinical Practice Guidelines","volume":"32","author":"Colombo","year":"2021","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101645_bib16","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.annonc.2021.11.013","article-title":"European experts\u2019 consensus: BRCA\/homologous recombination deficiency testing in first-line ovarian cancer","volume":"33","author":"Vergote","year":"2022","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.ijgc.2025.101645_bib17","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","article-title":"Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Gonz\u00e1lez-Mart\u00edn","year":"2023","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101645_bib18","doi-asserted-by":"crossref","first-page":"76","DOI":"10.2174\/1573404819666221021091708","article-title":"Frontline management of advanced epithelial ovarian cancer: a comprehensive statement by the Africa Middle East cancer inter-group [AMCI]","volume":"20","author":"Seoud","year":"2023","journal-title":"Curr Womens Health Rev"},{"key":"10.1016\/j.ijgc.2025.101645_bib19","article-title":"Optimizing treatment selection and sequencing decisions for first-line maintenance therapy of newly diagnosed advanced ovarian cancer","volume":"42","author":"Goh","year":"2022","journal-title":"Gynecol Oncol Rep"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101645_bib20","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","article-title":"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas","volume":"20","author":"Pennington","year":"2014","journal-title":"Clin Cancer Res."},{"issue":"6","key":"10.1016\/j.ijgc.2025.101645_bib21","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1111\/cas.15747","article-title":"Homologous recombination inquiry through ovarian malignancy investigations: JGOG3025 Study","volume":"114","author":"Yoshihara","year":"2023","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ijgc.2025.101645_bib22","article-title":"Homologous recombination deficiency associated with response to poly (ADP-ribose) polymerase inhibitors in ovarian cancer patients: the first real-world evidence from China","volume":"11","author":"Ni","year":"2021","journal-title":"Front Oncol"},{"issue":"10","key":"10.1016\/j.ijgc.2025.101645_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0040297","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration","volume":"4","author":"Vandenbroucke","year":"2007","journal-title":"PLoS Med"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101645_bib24","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3802\/jgo.2015.26.2.87","article-title":"FIGO\u2019s staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication","volume":"26","author":"Prat","year":"2015","journal-title":"J Gynecol Oncol"},{"issue":"suppl 16","key":"10.1016\/j.ijgc.2025.101645_bib25","article-title":"Distribution of homologous recombination deficiency (HRD) and BRCA mutations (m) detected by HRD-One test among Brazilian patients (pts) with newly diagnosed advanced epithelial ovarian, fallopian tube, or peritoneal cancer","volume":"40","author":"Scaranti","year":"2022","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.ijgc.2025.101645_bib26","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","article-title":"Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N Engl J Med."},{"issue":"13","key":"10.1016\/j.ijgc.2025.101645_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241310497","article-title":"HRD testing of ovarian cancer in routine practice: what are we dealing with?","volume":"24","author":"Kekeeva","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101645_bib28","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/cas.15518","article-title":"Japanese nationwide observational multicenter study of tumor BRCA1\/2 variant testing in advanced ovarian cancer","volume":"114","author":"Oda","year":"2023","journal-title":"Cancer Sci."}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25001689?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25001689?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T10:17:35Z","timestamp":1752574655000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X25001689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1048891X25001689"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.101645","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence of homologous recombination deficiency among women with newly diagnosed ovarian, primary peritoneal, and\/or fallopian tube cancer: the international HALO study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.101645","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of European Society of Gynaecological Oncology and the International Gynecologic Cancer Society.","name":"copyright","label":"Copyright"}],"article-number":"101645"}}